HCV - Weight-based Dosing


•Response to PegIntron and Ribavirin in HCV Patients with Body Weight >125 kg: the WIN-R Trial  11/03/06
•In ACCELERATE Trial, Highest SVR Seen in Patients Who Received the Longest Duration of Therapy with Pegasys and the Highest Mean Dose of Ribavirin Based on Body Weight  11/03/06
•Positive Impact of Higher Ribavirin Doses and Longer Duration of Therapy with Pegasys plus Ribavirin in HIV/HCV Coinfected Patients: The PRESCO Trial  11/03/06



Google_______________


 

 

 

 

 

 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka